Wednesday, Feb 10, 1993
South San Francisco, Calif. -- February 10, 1993 --On January 21, a French Court granted a petition by Eli Lilly and Company to revoke a portion of a Genentech Inc. French patent relating to methods for making growth hormone. Since the United States and French patent laws and the United States and French patents in litigation between Lilly and Genentech differ, Genentech, Inc. believes that this ruling will have no impact on the United States litigation between Eli Lilly and Company, the Regents of the University of California and Genentech, Inc. Genentech's t-PA patent encountered similar difficulties in litigation in the United Kingdom in 1987 but was ultimately upheld in the United States and Japan.
The litigations in the U.S. District Court in Indiana involve thirteen Genentech United States Patents being asserted against Eli Lilly and Company and the Regents of the University of California relating to human growth hormone, bovine growth hormone and porcine growth hormone. One patent relating to human growth hormone held by the Regents of the University of California and licensed to Eli Lilly and Company is being asserted against Genentech.
Additionally, Genentech has pending in the same court a breach of contract action against Eli Lilly and Company. This action involves the misuse of Genentech materials provided under an agreement directed to the development of recombinant human insulin.
Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant medical needs. The Company has headquarters in South San Francisco, California and is traded on the New York and Pacific Stock exchanges under the symbol GNE.
# # #